FRX
Sign in
Fennec Pharmaceuticals Inc
Save
–
Market cap
–
Current P/E
303.03x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Similar securities
Based on sector and market capitalization
Report issue